Cost-effectiveness in Clostridium difficile treatment decision-making
Cost-effectiveness in Clostridium difficile treatment decision-making作者机构：Ars Accessus Medica HAGA Teaching Hospital Clinical Microbiologist AMC iMTA and BMG EUR EUR AMC Europe-ExPro
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2015年第3卷第11期
页 面：935-941页
核心收录：
学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学]
主 题：Clostridium difficile infection Guidance Cost-effectiveness Model Standardisation Decision making
摘 要：AIM: To develop a framework for the clinical and health economic assessment for management of Clostridium difficile infection(CDI).METHODS: CDI has vast economic consequences emphasizing the need for innovative and cost effective solutions, which were aim of this study. A guidance model was developed for coverage decisions and guideline development in CDI. The model included pharmacotherapy with oral metronidazole or oral vancomycin, which is the mainstay for pharmacological treatment of CDI and is recommended by most treatment ***: A design for a patient-based cost-effectiveness model was developed, which can be used to estimate the cost-effectiveness of current and future treatment strategies in CDI. Patient-based outcomes were extrapolated to the population by including factors like, e.g., person-to-person transmission, isolation precautions and closing and cleaning wards of hospitals. CONCLUSION: The proposed framework for a population-based CDI model may be used for clinical and health economic assessments of CDI guidelines and coverage decisions for emerging treatments for CDI.
维普期刊数据库